|Articles|December 1, 2006
- Pharmaceutical Executive-12-01-2006
- Volume 0
- Issue 0
Eygptian Pharmaceuticals: Horizon 2010
Advertisement
Articles in this issue
about 19 years ago
Thoughtleader: Thomas Ebeling, Novartisabout 19 years ago
Forecasting Medicare: Price Controls in the Years Aheadabout 19 years ago
FDA vs. the Individualabout 19 years ago
Legal: E-headacheabout 19 years ago
From the Editor: Taken Awayabout 19 years ago
Global Report: Not So NICEabout 19 years ago
Confessions of a Serial Whistleblowerabout 19 years ago
Marketing to Professionals: Fax Me!about 19 years ago
PipelineNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Trending on PharmExec
1
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
2
FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
3
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
4
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
5
